Retina Implant Lengthens Headstart In Subretinal Implant Market
This article was originally published in Clinica
By CE-marking the Alpha AMS second-generation subretinal implant, Retina Implant has further widened the gap between itself and its rivals who are also developing devices to restore vision in patients blinded by degenerative retinal diseases such as retinitis pigmentosa.
You may also be interested in...
Australia's Bionic Vision Technologies (BVT) has raised AUS$23m ($18m) from Hong Kong-based investors, China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialize its retinal implant device. The technology could reach the market 3-5 years from now.
Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.